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A new study of disorders of sex development presents
an improved targeted next-generation sequencing
approach for their diagnosis.
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Disorders of (or differences in) sex development (DSD)
are a broad range of conditions that can affect repro-
ductive development and function in humans. Typically,
a child might first present with atypical genitalia at birth,
in such a way that it is not immediately possible to say
whether the newborn is a boy or girl. Other individuals
can present in childhood or teenage years, or even first
in adulthood. It is estimated that approximately 1 in
every 4000 people has DSD, although other variations of
these conditions (e.g. some forms of hypospadias) are
much more prevalent.
The past 25 years have seen significant progress in our
understanding of the genetic basis of sex development
and related conditions. In the early 1990s, SRY (‘sex-de-
termining region Y protein’) was identified as the main
Y-chromosomal driver for testis development, supported
by the generation of ‘Randy’, an XX mouse that devel-
oped testes and a male phenotype owing to the presence
of a Sry transgene [1]. SRY is also crucially important in
human testis determination, although only approxi-
mately 5% of individuals with testicular dysgenesis have
disruption of this transcription factor. More than 40
other genes have now been implicated in human DSD,
some of which can disrupt the male-typical development
pathway in individuals with a 46,XY karyotype, whereas* Correspondence: j.achermann@ucl.ac.uk
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veloping 46,XX child (Fig. 1). Sometimes biochemical
data, associated features or family history can help target
a diagnosis, especially in conditions affecting steroido-
genesis, but, for most children with gonadal dysgenesis
or hypospadias, a genetic cause is not typically found [2].Moving into the next generation
implications for counselling young people and their fam-
ilies about the likely course of their condition, associated
features that might need monitoring, hormonal function
and fertility, and gonadal tumor risk [2]. A specific gen-
etic diagnosis can also predict the likelihood of other
family members being affected. Traditionally, potential
candidate genes have been sequenced one at a time,
often as part of research studies. With the exception of
changes in steroidogenic factor-1 (NR5A1), the returns
are usually meagre [3]. This is in part due to the diverse
number of different genes that can cause DSD in af-
fected individuals, each of which only contributes a
small percentage to the overall picture.
In recent years, next-generation sequencing (NGS) ap-
proaches have provided great potential for upscaling
genetic analysis and investigating many genes in parallel.
Studies using whole-exome sequencing (WES) have in-
vestigated small cohorts of children with DSD and have
identified changes in genes known to be altered in DSD
as well as novel genes [4]. However, WES approaches
have the disadvantage of still being relatively expensive
and also producing extensive additional (often unrelated)
genetic information of uncertain importance.
An alternative approach, reported in a recent study by
Eggers and colleagues, is to use targeted panels of
known (and candidate) genes for high-throughput deep
sequencing to try to reach a diagnosis for DSD [5]. This
involved using a targeted panel (HaloPlex) that included
64 known DSD-associated genes (and 967 candidate
genes), in an international multi-centre study of 326le is distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 a–c Overview of some of the single genes currently
associated with disorders/differences of sex development (DSD).
Targeted next-generation sequencing (NGS) panels can be valuable
for the parallel analysis of many genes simultaneously, especially for
forms of 46,XY DSD (b) where the diagnosis is unclear. A study by
Eggers and colleagues [5] raises the possibility that variants in genes
traditionally associated with central hypogonadism/Kallmann syndrome
might also contribute to a 46,XY DSD phenotype
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proach involved many more individuals than previous
reports, as well as a wider range of genes and greater
depth of sequencing [6, 7]. The panel also included
many genes involved in central hypogonadism (central
hypogonadotropic hypogonadism, CHH).
The study by Eggers et al. has generated several im-
portant findings [5]. First, a likely specific genetic diag-
nosis was reached in 43% of the individuals tested.
Although functional studies were not performed, the
American College of Medical Genetic and Genomics
guidelines were used to determine the likely pathogen-
icity of the variants [8]. Second, it was surprising that
the analysis of trios (proband and parents) did not sig-
nificantly improve the diagnostic yield. As many genetic
variants associated with DSD arise as de novo dominant
conditions, it would have been anticipated that trio ana-
lysis would have helped to identify de novo changes and
thereby strengthen evidence for likely pathogenicity.
Third, 13 individuals with 46,XY DSD had more than
one curated variant in a diagnostic DSD gene detected,
suggesting a potential oligogenic inheritance in some sit-
uations. Finally, there was an enrichment of likely patho-
genic variants found in several genes (e.g. CHD7,
WDR11, FGF8/FGFR1) that are traditionally associatedwith CHH/Kallmann syndrome. CHH is a hypothal-
amic–pituitary condition in which release of the gonad-
stimulating hormones follicle-stimulating hormone
(FSH) and luteinizing hormone (LH) is reduced. In the
current model of human sex development, congenital
gonadotropin insufficiency should only affect penile
growth (length) and testis descent in the later stages of
fetal development. The identification of changes in these
genes in individuals with hypospadias and other more
marked variations in genital anatomy suggest that some
genes function at multiple levels throughout the hypo-
thalamic–pituitary–gonadal axis and support previous
findings by Baxter and colleagues [4].
Several limitations of this study must also be
highlighted. With more-detailed clinical and biochemical
phenotyping, it is possible that a diagnosis could still
have been reached in a very small number of children
using single-gene analysis (e.g. WT1 in renal failure or
STAR in lipoid congenital adrenal hyperplasia) [2]. Fur-
thermore, analysis of several classic congenital adrenal
hyperplasia (CAH) genes (e.g. CYP21A2) can be difficult
using targeted capture and NGS because of the presence
of a pseudogene. As CAH is a common and important
diagnosis to make, a combination of biochemical ana-
lysis followed by single-gene testing is still the best ap-
proach, and accordingly children with CAH were not
entered into this study [2]. Finally, different personal
and cultural views on genetic testing need to be consid-
ered. Unlocking genetic knowledge is often of benefit,
but can also carry a burden of information, especially in
such a sensitive area as reproductive development. En-
gagement and education of families and young people,
together with balanced information and consent, are im-
portant. While bearing all these considerations in mind,
offering a more comprehensive panel-based approach to
genetic testing, as described by Eggers and colleagues,
certainly seems one way forward.Where do we go from here?
High-throughput panel-based genetic analysis has now
come of age in many settings, and similar studies have
recently been reported for other endocrine conditions.
For example, De Franco and colleagues used a targeted
NGS panel as part of their comprehensive evaluation of
an international cohort of more than 1000 children
with neonatal diabetes, where a final molecular diagno-
sis was reached in 82% [9]. Similarly, Guran and collab-
orators studied almost 100 patients with primary
adrenal insufficiency of unknown cause from a national
cohort study in Turkey and reached a genetic diagnosis
in 81% [9, 10].
Why then is the diagnostic yield in DSD not more
than 50%? Several reasons could account for this:
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analysis of single genes, and so the diagnostic yield
of the array would likely have been higher if the
children had been recruited without any prior
testing.
2. Key novel genes involved in DSD might yet be
discovered. For example, important variants could
have been detected in some of the many candidate
genes included in the study by Eggers et al. but not
included in their report; novel variants might be
found in WES studies of DSD currently under way;
and genomic changes in enhancers or regulatory
regions might be detected by whole-genome
sequencing approaches, such as the 100,000 genomes
project. International collaborations might be needed
to understand the potential contribution of rare
variants in diverse genes of unknown function, or to
piece together any potential role for complex digenic
or oligogenic interactions. Data analysis in DSD can
be complicated further by the relative lack of large
pedigrees as these genetic conditions often result in
infertility and are not transmitted; by the observation
of sex-limited inheritance patterns (e.g. where
mothers can carry an autosomal dominant variant
but are not affected); and by variable phenotypic
penetrance. Even where there is a family history,
this might be private information that is not widely
shared among family members.
3. Several studies have shown that copy-number
variants can be involved in DSD, which are not so
easily detected using current NGS technologies or
bioinformatic pipelines.
4. Somatic changes in key factors during early
embryonic life can affect organ development in a
tissue- and time-specific manner. Such events would
not be detected unless the specific tissues were ana-
lysed (e.g. gonad), and this might be impossible once
an organ has undergone fibrosis or has regressed.
5. Epigenetic or environmental factors can influence
early gonad development or genital anatomy either
alone or in combination with rare genetic events.
Despite these many challenges with DSD, human gen-
etics has entered an exciting era, and the study by Eggers
and colleagues shows that the field is making progress.
Translation of research approaches into clinical service
is an important short-term goal, and providing benefits
for young people and their family must remain very
much the focus of investigators’ work. Smaller-scale tar-
geted NGS panels are already available in clinical service
in some centres, with the main drawback being the need
to batch several samples together for analysis, which can
slow down turnaround times. In the future, larger multi-
disorder panels, whole-exome and even whole-genomeapproaches might be used as first-line investigations,
with the initial bioinformatics analysis restricted only to
DSD-related genes. In most places, however, these ap-
proaches are still limited by cost and capacity, and so in
the meantime specific targeted panels have a lot to offer.
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